contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


health-canada-grants-ivd-approval-to-devysers-ngs-based-chimerism-test-the-first-of-its-kind-in-canada

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.

Devyser Diagnostics

Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With ...

<div class="mfn-preamble"><p><strong>Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada. With this we set a new standard for post-transplant monitoring nationwide as this is the first ever IVD-marked chimerism test to receive approval in Canada.</strong></p></div><div class="mfn-body"><p>The approval underscores Devyser’s dedication to providing laboratories and clinicians with high-precision, user-friendly solutions for post-transplant monitoring. <strong>One Lambda Devyser Chimerism</strong> enables highly accurate quantification of donor and recipient DNA following hematopoietic stem cell transplantation (HSCT) allowing clinicians to detect graft rejection or disease relapse at an early stage. <strong>Advyser Chimerism</strong> is our data analysis software that complements the assay by streamlining interpretation, reporting, and data management.&nbsp;</p><p>"Achieving Class III IVD approval in Canada and being the first chimerism assay to do so, is a true reflection of teamwork,” said Jan Wahlström, CEO, Devyser. “This also reflects Devyser’s commitment to supporting laboratories, clinicians, and patients through reliable, high-quality molecular diagnostic solutions."&nbsp;</p><p>With this approval, Canadian laboratories can now implement Devyser’s complete chimerism workflow, benefiting from a simplified process, rapid turnaround, and enhanced confidence in post-transplant monitoring.&nbsp;</p><p><em>One Lambda Devyser Chimerism and Advyser Chimerism are currently available under an exclusive collaboration and distribution agreement between Devyser and Thermo Fisher Scientific.</em>&nbsp;</p></div><div class="mfn-footer mfn-contacts mfn-6ebf9f6a6a18"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Jan Wahlström, CEO&nbsp;<br>E-mail: <a rel="noopener" href="mailto:ir@devyser.com">ir@devyser.com</a><br>Telephone: +46 8&nbsp;562 158&nbsp;50<br>&nbsp;<br>Theis Kipling, CCO<br>E-mail: <a rel="noopener" href="mailto:ir@devyser.com">ir@devyser.com</a>&nbsp;<br>Telephone: +46 8&nbsp;562 158&nbsp;50</p></div><div class="mfn-footer mfn-about mfn-89538f97f28b"><p><strong class="mfn-heading-1">About Devyser</strong><br>Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency. &nbsp;</p><p>Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes. &nbsp;</p><p>We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US. &nbsp;</p><p>Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio. &nbsp;</p><p>Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company´s Certified Adviser is Redeye AB. &nbsp;</p><p>Discover how we're shaping the future of lab diagnostics at <a rel="noopener" href="http://www.devyser.com/">www.devyser.com</a>. &nbsp;</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/406b6634-50d0-4260-9357-0d0e784993ea/health-canada-grants-ivd-approval-to-devysers-ngs-based-chimerism-test-the-first-of-its-kind-in-canada.pdf" class="mfn-generated mfn-primary">Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada</a></p></div>

Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada